Improved gene delivery and T Cell editing using cell free DNA and novel non viral delivery solutions

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Improved gene delivery and T Cell editing using cell free DNA and novel non viral delivery solutions

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

Switching to enzymatically produced DNA formats and optimized non-viral delivery vehicles can address two of the most persistent bottlenecks in gene therapy development: DNA toxicity and suboptimal delivery efficiency. This session presents comparative data from two complementary platforms, examining how advanced DNA payload formats and lipid and polymer-based delivery systems can together reduce immune sensing, improve therapeutic dosing, and enhance T cell editing outcomes.

Attendees will see head-to-head data comparing dbDNA and mbDNA against plasmid DNA across multiple delivery contexts, including systemic and local in vivo delivery and HDR-based T cell editing, alongside performance data for a preassembled lipid-based nanoparticle platform for RNA and DNA delivery into T cells.

Register now to understand how combining advances in payload design and delivery platform selection can reduce reliance on viral vectors and support more efficient, scalable non-viral gene therapy programs.

Attend this session to:

Review in vivo data demonstrating superior expression magnitude and durability of dbDNA versus plasmid DNA across multiple organs after systemic delivery, and in muscle tissue via local administration using non-viral delivery solutions
Examine T cell editing data showing improved HDR efficiency and cell viability using mbDNA and dbDNA compared to plasmid DNA, with implications for repeat dosing and immune evasion
Explore the performance of a pre-formed vesicles (PFVs) solution, LipidBrick® Cell Ready, coupled with a lipid-based nanoparticle platform for stable editing and transient expression in T cells
Gain practical guidance on selecting DNA payload formats and delivery formulations based on application requirements, without the need to develop these capabilities in-house

Claire Gueguen, PhD

R&D Life Sciences Manager at Sartorius

Dr. Claire Guéguen is R&D Life Sciences Manager at Sartorius Polyplus. After obtaining her PhD in Immunology, she worked for five years at Adaptimmune in the R&D Department on TCR T-cell therapies and on the generation of allogeneic T cells from iPSCs. She now oversees the screening and the development of innovative transfection reagents for in vitro and in vivo nucleic acid delivery, including the transfection of immune and stems cells.

Peter Archibald, PhD

Associate Director of Applications at Touchlight

Dr. Peter Archibald is Associate Director of Applications at Touchlight, leading global viral vector applications for Touchlight's enzymatic DNA, as well as supporting customers across RNA, non-viral gene therapy and gene editing applications. Peter is a bioprocess development specialist with over 10 years of experience in cell & gene therapy and viral vector manufacturing. He completed his PhD in Regenerative Medicine at Loughborough University, where he focused on scalable stem cell bioprocess development. Peter then joined GSK, where he developed and scaled AAV and Lentiviral vector production platforms, leading GMP tech transfers and supporting multiple IND/IMPD submissions for clinical programmes. He went on to lead upstream development at Rentschler Biopharma, establishing new AAV and Lentiviral vector capabilities and guiding client projects from process development to GMP, before joining Touchlight in 2025.

In 30 Days

You have registered for this webinar